Skip to main content
Literatur
Zurück zum Zitat Arkkila PE, Seppälä K, Kosunen TU, Sipponen P, Mäkinen J, Rautelin H, Färkkilä M (2005) Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol 17:93–101CrossRefPubMed Arkkila PE, Seppälä K, Kosunen TU, Sipponen P, Mäkinen J, Rautelin H, Färkkilä M (2005) Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol 17:93–101CrossRefPubMed
Zurück zum Zitat Ford AC, Delaney B, Forman D, Moayyedi P (2006) Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database od Systematic Reviews Issue 2 (Art. No.: CD003840) doi:10.1002/14651858.CD003840.pub4 Ford AC, Delaney B, Forman D, Moayyedi P (2006) Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database od Systematic Reviews Issue 2 (Art. No.: CD003840) doi:10.1002/14651858.CD003840.pub4
Zurück zum Zitat Fuccio L, Zagari RM, Eusebio LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F (2009) Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk of gastric cancer? Ann Intern Med 151:121–128CrossRefPubMed Fuccio L, Zagari RM, Eusebio LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F (2009) Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk of gastric cancer? Ann Intern Med 151:121–128CrossRefPubMed
Zurück zum Zitat Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D (2009) Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 104:3069–3079CrossRefPubMed Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D (2009) Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 104:3069–3079CrossRefPubMed
Zurück zum Zitat Graham DY, Fischbach L (2010) Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59:1143–1153CrossRefPubMed Graham DY, Fischbach L (2010) Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59:1143–1153CrossRefPubMed
Zurück zum Zitat Houghton J, Wang TC (2005) Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 128:1567–1578CrossRefPubMed Houghton J, Wang TC (2005) Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 128:1567–1578CrossRefPubMed
Zurück zum Zitat Luther J, Higgings PDR, Schoenfeld PS, Moayyedi P, Vakil N, Chey W (2010) Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 105:65–73CrossRefPubMed Luther J, Higgings PDR, Schoenfeld PS, Moayyedi P, Vakil N, Chey W (2010) Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 105:65–73CrossRefPubMed
Zurück zum Zitat Petersen K-U, Labenz J (2010) Protonenpumpenhemmer: Standort 2010. Verdauungskrankheiten 28(Suppl 1):S1–S48 Petersen K-U, Labenz J (2010) Protonenpumpenhemmer: Standort 2010. Verdauungskrankheiten 28(Suppl 1):S1–S48
Zurück zum Zitat Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY (2010) Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 8:36–41PubMedCentralCrossRefPubMed Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY (2010) Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 8:36–41PubMedCentralCrossRefPubMed
Zurück zum Zitat Morgner A, Miehlke S, Labenz J (2007) Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opin Pharmacother 8:975–988CrossRefPubMed Morgner A, Miehlke S, Labenz J (2007) Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opin Pharmacother 8:975–988CrossRefPubMed
Zurück zum Zitat Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC (2010) Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138:82–88CrossRefPubMed Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC (2010) Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138:82–88CrossRefPubMed
Zurück zum Zitat Petersen K-U, Labenz J (2010) Protonenpumpenhemmer: Standort 2010. Verdauungskrankheiten 28(Suppl 1):S1–S48 Petersen K-U, Labenz J (2010) Protonenpumpenhemmer: Standort 2010. Verdauungskrankheiten 28(Suppl 1):S1–S48
Zurück zum Zitat Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V (2000) Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 18:463–467PubMed Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V (2000) Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 18:463–467PubMed
Zurück zum Zitat Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C (2006) Prevention of ulcers in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101:701–710CrossRefPubMed Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C (2006) Prevention of ulcers in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101:701–710CrossRefPubMed
Zurück zum Zitat Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J (2009) Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 104:1475–1482CrossRefPubMed Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J (2009) Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 104:1475–1482CrossRefPubMed
Zurück zum Zitat Van Soest EM, Sturkenboom MCJM, Dieleman JP, Verhamme KMC, Siersma PD, Kuipers EJ (2007) Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 26:265–275CrossRefPubMed Van Soest EM, Sturkenboom MCJM, Dieleman JP, Verhamme KMC, Siersma PD, Kuipers EJ (2007) Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 26:265–275CrossRefPubMed
Zurück zum Zitat Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ (2005) Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22:795–801CrossRefPubMed Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ (2005) Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22:795–801CrossRefPubMed
Zurück zum Zitat Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Rácz I, Tchernev K, Karamanolis D, Roda E, Hawkey C, Nauclér E, Svedberg LE (2008) Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continous use of low-dose aspirin. Am J Gastroenterol 103:2465–2473CrossRefPubMed Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Rácz I, Tchernev K, Karamanolis D, Roda E, Hawkey C, Nauclér E, Svedberg LE (2008) Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continous use of low-dose aspirin. Am J Gastroenterol 103:2465–2473CrossRefPubMed
Zurück zum Zitat Adamu MA, Weck MN, Gao L, Brenner H (2010) Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol 25:439–448CrossRefPubMed Adamu MA, Weck MN, Gao L, Brenner H (2010) Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol 25:439–448CrossRefPubMed
Zurück zum Zitat Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney Systeme. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161CrossRefPubMed Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney Systeme. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161CrossRefPubMed
Zurück zum Zitat Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T (2011) Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinomas development of Mongolian gerbils infected with Helicobacter pylori. Gut 60:624–630. doi:10.1136/gut.2010.207662CrossRefPubMed Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T (2011) Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinomas development of Mongolian gerbils infected with Helicobacter pylori. Gut 60:624–630. doi:10.1136/gut.2010.207662CrossRefPubMed
Zurück zum Zitat Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW (1992) Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 102:1409–1418PubMed Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW (1992) Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 102:1409–1418PubMed
Zurück zum Zitat Kosunen TU, Pukkala E, Sama S, Sepällä K, Aromaa A, Knekt P, Rautelin H (2010) Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study. Int J Cancer 128:433–439CrossRefPubMed Kosunen TU, Pukkala E, Sama S, Sepällä K, Aromaa A, Knekt P, Rautelin H (2010) Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study. Int J Cancer 128:433–439CrossRefPubMed
Zurück zum Zitat Kuipers EJ, Uyterlinde AM, Pena AS, Rosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG (1995) Long-term sequelae of Helicobacter pylori gastritis. Lancet 345:1525–1528CrossRefPubMed Kuipers EJ, Uyterlinde AM, Pena AS, Rosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG (1995) Long-term sequelae of Helicobacter pylori gastritis. Lancet 345:1525–1528CrossRefPubMed
Zurück zum Zitat Ricci C, Vakil N, Rugge M, Gatta L, Perna F, Osborn JF, Russo VM, Tampieri A, Bernabucci V, Miglioli M, Vaira D (2004) Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 99:1910–1915CrossRefPubMed Ricci C, Vakil N, Rugge M, Gatta L, Perna F, Osborn JF, Russo VM, Tampieri A, Bernabucci V, Miglioli M, Vaira D (2004) Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 99:1910–1915CrossRefPubMed
Zurück zum Zitat Sipponen P, Härkönen M (2010) Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol 45:133–138CrossRefPubMed Sipponen P, Härkönen M (2010) Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol 45:133–138CrossRefPubMed
Zurück zum Zitat Vanella L, Lahner E, Osborn J, Bordi C, Miglioni M, Delle Fave G, Annibale B (2010) Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 31:1042–1059 Vanella L, Lahner E, Osborn J, Bordi C, Miglioni M, Delle Fave G, Annibale B (2010) Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 31:1042–1059
Metadaten
Titel
Entzündliche Erkrankungen des Magens und Duodenums
verfasst von
Joachim Labenz, Prof. Dr. med.
Guido Schumacher, Prof. Dr. med.
Copyright-Jahr
2015
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-642-14301-4_20

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.